Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: lactose monohydrate; mannitol; magnesium stearate; hypromellose; silicon dioxide; sodium acetate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; silicon dioxide; lactose monohydrate; magnesium stearate; mannitol; sodium acetate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - gliclazide - oral tablet - 80mg

Ireland - English - HPRA (Health Products Regulatory Authority)

bristol laboratories limited - gliclazide - prolonged-release tablet - 30 milligram(s) - sulfonamides, urea derivatives; gliclazide

Ireland - English - HPRA (Health Products Regulatory Authority)

brillpharma (ireland) limited - gliclazide - prolonged-release tablet - 30 milligram(s) - sulfonamides, urea derivatives; gliclazide

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - gliclazide 80mg - tablet - 80 mg - active: gliclazide 80mg excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - gliclazide is indicated for diabetes mellitus of the maturity onset type, which cannot be controlled by diet alone

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose monohydrate; magnesium stearate; maltodextrin; hypromellose; colloidal anhydrous silica - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg-120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; lactose monohydrate; magnesium stearate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: magnesium stearate; lactose monohydrate; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: hypromellose; povidone; calcium hydrogen phosphate dihydrate; magnesium stearate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.